Universe Pharmaceuticals (UPC)
NASDAQ:UPC
Want to see UPC full AI Analyst Report?
UPC Stock Chart & Stats
$4.22
-$0.02(-3.13%)
At close: 4:00 PM EST
$4.22
-$0.02(-3.13%)
Day’s Range― - ―
52-Week Range$2.00 - $11.00
Previous CloseN/A
Volume250.22K
Average Volume (3M)955.25K
Market Cap
$1.86M
Enterprise Value-$22.70M
Total Cash (Recent Filing)$33.59M
Total Debt (Recent Filing)$9.26M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Aug 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-945.09
Shares Outstanding631,761
10 Day Avg. Volume2,486,504
30 Day Avg. Volume955,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00082
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-12.18
Enterprise Value/Revenue-1.27
Enterprise Value/Gross Profit-3.60
Enterprise Value/Ebitda7.77
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Conservative Balance SheetA low debt-to-equity ratio and modest absolute debt provide financial flexibility and reduce refinancing risk over the medium term. This conservatism supports the company through continued operating losses and gives management room to invest in R&D or transitions without immediate solvency pressure.
Gross Margin Rebound And Improving Margins In 2025A rebound in gross margin and measurable improvement in net margin indicate the business may be stabilizing unit economics or benefiting from cost actions. If sustained, better margins can reduce cash burn and make a future recovery more durable, even if top-line remains challenged.
2026 Equity Incentive Plan To Align And Retain TalentA formal long-term incentive program signals a structural commitment to talent retention and alignment of management with shareholder outcomes. Over months, this can improve execution continuity, encourage performance-based decision-making, and support product development or commercialization efforts.
Bears Say
Multi-year Revenue DeclineSustained revenue decline erodes scale, undermines pricing power and the ability to cover fixed costs. Over a 2–6 month horizon the structural revenue trend limits margin leverage and requires either new product traction or market share recovery to restore profitable growth.
Persistent Negative Operating And Free Cash FlowOngoing negative operating and free cash flow means the company is consuming cash to fund operations, increasing reliance on external financing or equity dilution. This structural cash burn constrains strategic options and raises risk of capital access stress if losses persist.
Concentrated Voting Control By CEOA single insider controlling ~75% of votes creates governance concentration that can limit minority shareholders' influence on strategy or oversight. Over time this raises execution risk if governance checks are weak and can affect strategic decisions and capital allocation priorities.
Universe Pharmaceuticals News
UPC FAQ
What was Universe Pharmaceuticals’s price range in the past 12 months?
Universe Pharmaceuticals lowest stock price was $2.00 and its highest was $11.00 in the past 12 months.
What is Universe Pharmaceuticals’s market cap?
Universe Pharmaceuticals’s market cap is $1.86M.
When is Universe Pharmaceuticals’s upcoming earnings report date?
Universe Pharmaceuticals’s upcoming earnings report date is Aug 03, 2026 which is in 45 days.
How were Universe Pharmaceuticals’s earnings last quarter?
Universe Pharmaceuticals released its earnings results on Feb 03, 2026. The company reported -$0.688 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.688.
Is Universe Pharmaceuticals overvalued?
According to Wall Street analysts Universe Pharmaceuticals’s price is currently Overvalued.
Does Universe Pharmaceuticals pay dividends?
Universe Pharmaceuticals does not currently pay dividends.
What is Universe Pharmaceuticals’s EPS estimate?
Universe Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Universe Pharmaceuticals have?
Universe Pharmaceuticals has 631,761 shares outstanding.
What happened to Universe Pharmaceuticals’s price movement after its last earnings report?
Universe Pharmaceuticals reported an EPS of -$0.688 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.721%.
Which hedge fund is a major shareholder of Universe Pharmaceuticals?
Currently, no hedge funds are holding shares in UPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Universe Pharmaceuticals
Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These remedies are designed to address common chronic health issues prevalent among the elderly, promoting physical well-being and longevity, in addition to offering medications for cold and flu symptoms. Beyond its own manufactured goods, UPC also functions as a distributor and vendor for a diverse range of third-party products. This extensive portfolio includes biomedical drugs, medical instruments, traditional Chinese medicine 'pieces' (raw ingredients), and various dietary supplements. Its clientele spans across the healthcare sector, encompassing other pharmaceutical companies, hospitals, clinics, and major drugstore chains. Established in 2019, the company's operations are headquartered in Ji'An, China, and it functions as a subsidiary of Sununion Holding Group Limited.
Technical Analysis
China Pharma Holdings
―
RedHill Biopharma
―
China SXT Pharmaceuticals
―
PainReform
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
Options Prices
Currently, No data available
---